Pharmaceutical boards, regulatory agencies, and drug manufacturers work to ensure that they maintain the highest standards for public health and safety.
Finding a best-fit or combination of pre-clinical models in immuno-oncology drug development poses a unique series of challenges. Foundational knowledge of the tumor microenvironment and its evasion of the immune system continues to evolve based on emerging data from areas including regulation, academia, and industry.
Lab manager are using different staffing models to help reduce costs and accelerate their lab’s workflow.
The complex relationship between a virus and its host is one of the hottest topics in science right now, and has been given considerable attention in recent weeks as a result of the race to understand the virus that causes COVID-19 and its potential vulnerabilities.
Within a few weeks of the outbreak, scientists in Wuhan, China were able to isolate and sequence the new highly contagious SARS-CoV-2 viral genome.
Prescription and over-the-counter medicines need to meet the expectations of the public, which requires that they’re safe, effective, and transparent about any possible risks. To do this, there have to be standards and regulations in place that guarantee pharmaceutical quality.
Regardless if you are moving one instrument across a campus or 100 instruments across the globe, relocating your lab is never an easy task. We’ve seen it firsthand – poor planning, limited time, and mismanagement can result in a disastrous move.
The COVID-19 pandemic has affected nearly every industry, with many measures intended to prevent spread i.e. social-distancing, masks, stay-in-place - remain firmly in place, significantly altering the way life is lived and business is conducted.
More and more researchers are turning to 3D cell models for high-content screening to better understand diseases and to test potential therapeutics.